Onset: 2-4 weeks for libido + morning erection changes. 4-12 weeks for any measurable T or body composition effects. Acute dose-day effects: subtle if present — most users describe nothing distinct from a single dose. Not a stimulant feel like caffeine or modafinil; not a sedative either.

Peak effects (weeks 4-12 of daily use):

• Libido increase — most reproducible subjective effect. Higher baseline desire, more frequent spontaneous arousal, easier psychogenic erection. Comparable to (though milder than) a TRT first-month bump in self-reports.
• Morning erection frequency — often the earliest objective signal users notice (week 1-3).
• Subjective stress resilience — "irritability budget" stretches further. Less reactive to training fatigue, work stress, sleep debt. Likely the cortisol-blunting mechanism made subjective.
• Energy / drive — variable. Some users describe a clean "more interested in things" feel; others report nothing.
• Mood lift — modest; reproducible in stressed/borderline-low-T subgroups, less so in already-thriving young men.

Non-effects (what people overclaim):

• Strength PRs from supplementation alone are not the typical experience in healthy young men (Chen 2019 supports this null).
• "Massive testosterone surge" subjective feel is not characteristic. If a user describes amphetamine-like energy or rapid muscle pump within days of starting, suspect placebo or product adulteration (sildenafil analogues are documented contaminants in some tongkat ali brands).
• Aggression / "alpha" personality shifts — overclaimed by influencer marketing. Not a robust signal in the trials.

Characteristic side-effect feel:

• Mild insomnia or shifted sleep if dosed late in the day (>noon at higher doses)
• Mild restlessness / heart-rate awareness at 400+ mg, especially first week
• Rarely: nausea, headache, dry mouth — usually transient

Variability: ~15-25% of users report no meaningful subjective effect across 8-12 weeks. Plausible non-responders: men with already-optimal T + low cortisol baseline (e.g., young athletes), CYP-mediated rapid clearers, those on unstandardized product with low actual eurycomanone content.

• Pharmacodynamic tolerance: Not well-characterized as a real phenomenon. No receptor-desensitization data; mechanism (SHBG modulation + cortisol blunting) doesn't predict classical tolerance. Most users on continuous Physta dosing through 12-week trials maintain effect.
• Subjective tolerance / fading effect: Common report, ambiguous. Probably mostly novelty fading + regression to baseline rather than true tolerance.
• Recommended cycle: Continuous 8-12 week blocks with 2-4 week washouts is a reasonable conservative pattern. Strict 5-on/2-off is folklore — no pharmacological basis. Some users run continuous for 6-12 months without issue, but LFT monitoring becomes more important the longer the chronic exposure.
• Reset protocol: A 2-4 week washout fully resets any subjective tolerance and provides an honest "off-baseline" comparison. Useful for n=1 evaluation of whether the supplement is actually doing anything.
• Cross-tolerance: None documented. Stacking with other phytoandrogens (Cistanche, Fadogia, Shilajit) doesn't predict tolerance interactions but may have additive risks — see Stacking.

Synergistic with

• Zinc (15-30 mg/day): Co-factor for testosterone synthesis; deficiency is common in athletes. Synergistic and almost always co-stacked.
• Vitamin D3 (4000 IU/day, with K2): Independent T support evidence; standard hormone-optimization base layer. The community aggregate confirms — 213 co-uses, most-paired compound in the dopamine.club dataset.
• Magnesium glycinate (300-400 mg, PM): Lowers SHBG independently; complements the SHBG-reduction mechanism. Standard sleep + recovery base layer.
• Boron (3-10 mg/day): Documented to lower SHBG and raise free-T; mechanistically complementary; cheap.
• Ashwagandha (KSM-66, 600 mg/day): Cortisol blunting via different pathway (likely 5-HT/GABA mediated); modest T-elevation evidence. Complementary stress-axis support. Many users stack the two for cortisol management.
• Shilajit (fulvic acid 300-500 mg/day): Increases total T + DHEAS in older men; commonly co-stacked in commercial T-booster products. Community aggregate confirms — 187 co-uses. Mechanistically plausible synergy but no head-to-head pair trials.
• Fadogia agrestis (600 mg/day): Influencer-popular co-stack ("Huberman stack"); evidence for fadogia itself is much weaker than tongkat ali — animal data only, no human RCTs. Stack at your own risk; the fadogia portion is the weak link.
• Cistanche tubulosa (500 mg/day): Phytoandrogenic stack partner; modest evidence; community-popular co-stack (184 co-uses in dopamine.club aggregate).
• Creatine monohydrate (5 g/day): Independent strength + recovery benefits, no interaction concerns, commonly co-stacked (189 co-uses).

Avoid stacking with

• TRT or exogenous testosterone: Redundant + risk of supraphysiological androgen levels, elevated hematocrit, mood instability. The dopamine.club interaction notes flag this with moderate confidence.
• Strong aromatase inhibitors (anastrozole, exemestane): If using tongkat ali for the (modest, debated) AI effect, doubling up with a real AI risks crashing estradiol — bone, joint, libido consequences.
• Finasteride: Theoretical interaction (more T substrate × blocked DHT conversion); clinical significance unclear. Worth flagging if used together.
• Hepatotoxic compounds (1-andro, methylstenbolone, alcohol-heavy use): Additive liver load. Avoid stacking with any compound carrying its own hepatotoxicity signal.
• High-dose exogenous estradiol therapy (HRT, gender-affirming care): Eurycomanone has SERM-like anti-estrogenic activity; may reduce HRT efficacy. Real interaction, documented in literature, flagged in dopamine.club interaction data.
• PDE5 inhibitors (sildenafil, tadalafil): Risk of additive hypotension/priapism; bigger concern is that some tongkat ali products are adulterated with PDE5 analogues — stacking real PDE5 with potentially-spiked supplement is the actual risk vector. Buy standardized product only.

Neutral / safe co-administration

• All standard nootropics (caffeine, L-theanine, alpha-GPC, lion's mane, bacopa) — no interactions
• Modafinil (theoretical additive sympathomimetic concern in interaction databases, but minimal practical signal at standard doses)
• Creatine, beta-alanine, citrulline, betaine — neutral
• Omega-3, curcumin, NAC — neutral (some hepatoprotection potential from NAC)
• SSRI/SNRI — no documented interactions

• Metabolism: Tongkat ali quassinoids are metabolized primarily via hepatic CYP-mediated phase I + glucuronidation. Not a well-characterized CYP inducer or inhibitor at standard doses; theoretical concern higher with chronic high-dose use.
• Anticoagulants (warfarin, DOACs): Theoretical platelet/coagulation effects from quassinoid fraction — clinical significance minor but worth monitoring INR if on warfarin. Not a hard contraindication.
• Antidiabetics (metformin, sulfonylureas, semaglutide/tirzepatide): Tongkat ali has mild glucose-lowering activity in animal models. Theoretical additive hypoglycemia; monitor BG if on antidiabetic medications. The dopamine.club interaction notes flag this with low-to-moderate confidence across multiple antidiabetic agents.
• Immunosuppressants (cyclosporine, tacrolimus): Quassinoid fraction may have mild immunomodulatory activity; theoretical concern in transplant patients.
• Lithium: Theoretical renal-clearance interaction; lithium's narrow therapeutic window makes any potential interaction worth flagging.
• MAO inhibitors (selegiline, phenelzine, tranylcypromine): Theoretical sympathomimetic potentiation from alkaloid fraction; clinical case literature absent but principle of caution applies — co-use should be monitored.
• Hormonal contraceptives: No direct interaction documented; theoretical concern about SERM-like activity of eurycomanone interfering with estrogenic contraceptive components is mostly speculative.
• Hormone replacement therapy (exogenous estradiol): Real interaction — eurycomanone's anti-estrogenic activity may reduce HRT efficacy. Documented in animal models; clinical relevance plausible. Avoid stacking.
• Exogenous testosterone (TRT): Additive androgenic effect risk; monitor hematocrit and total-T if combined (and reconsider whether the natural supplement adds anything to a pharmaceutical regimen).
• PDE5 inhibitors (sildenafil, tadalafil): Theoretical additive vasodilation; bigger real risk is product adulteration (PDE5 analogues spiked into supplements). Use only third-party-tested standardized products.

• CYP-mediated clearance variants: Not specifically mapped for tongkat ali. Speculative: CYP3A4/CYP2D6 polymorphisms likely affect quassinoid clearance and dose-response but no clinical PGx data exists. No actionable PGx for tongkat ali response as of 2026.
• SHBG gene (SHBG): Polymorphisms at rs1799941 and rs6259 affect baseline SHBG levels and androgen bioavailability. Carriers of low-SHBG variants have less room for SHBG-modulating supplements to help — theoretical predictor of non-response.
• AR (androgen receptor) CAG repeat length: Shorter CAG repeats (more sensitive AR) may amplify subjective effects of even small free-T changes; longer repeats may blunt response. Not validated for tongkat ali specifically.
• CYP19A1 (aromatase) variants: If tongkat ali has a real aromatase-inhibitory component, CYP19A1 polymorphisms may affect response. Speculative.
• Practical implication for Dylan: Once 23andMe results land (~June 2026), check SHBG and AR variants via Promethease for context — but don't expect them to be decisive for the supplement decision. The most-likely-honest answer is that genotype-mediated response prediction is not yet useful for tongkat ali.

Brand-by-brand notes (Physta-standardized, recommended):

• Double Wood Tongkat Ali (Physta, 400 mg/capsule) — Amazon, ~$25 for 60 caps; consistent quality, third-party tested.
• Pure Tongkat Ali (Physta, 200 mg/capsule) — typically iHerb or direct; good entry-level option for 200 mg/day protocol.
• Nutricost Tongkat Ali (Physta) — bulk-economy brand, COA available, standard quality.
• 1st Phorm Royal-21 or Genius Brand — premium-priced; same Physta active, more expensive packaging.

For Dylan: order Double Wood or Pure Tongkat Ali (Physta-standardized) at 200 mg/day × 8-week trial; ~$25-30 for the trial period. Avoid generic non-Physta "100:1 root extract" products even if cheaper — the mercury contamination signal in unstandardized Southeast Asian product is real, even if low-base-rate.

Payment / availability: Widely available on Amazon, iHerb, vendor direct. No prescription required. No legal restrictions in any major Western jurisdiction.

Baseline (before starting)

• Total testosterone + free testosterone + SHBG — primary hormonal endpoints. AM, fasted, ideally 7-9 AM draw.
• Cortisol — AM cortisol baseline; salivary cortisol diurnal curve if available (the more accurate measure given Talbott 2013 used salivary).
• Estradiol (E2) — if any concern about the aromatase-inhibition angle or stacking with finasteride/HRT.
• LH + FSH — establishes whether any T response is via HPG-axis stimulation vs. SHBG modulation.
• DHEAS — common-stack synergy marker (shilajit reads here).
• ALT, AST, GGT — liver baseline; mandatory if planning >8 week trial.
• CBC — hematocrit baseline (TRT-class compounds raise hematocrit; tongkat ali should not, but verify).
• Subjective libido / morning erection frequency — VAS or 1-week diary.
• AMS (Aging Male Symptoms) score if 35+ or any subclinical hypogonadism suspicion — used in Chinnappan 2021.
• Stress / mood VAS (1-10 daily) for 7-14 days pre-start, especially for the cortisol-blunting use case.

During use

• Weeks 1-4: Subjective tracking — sleep onset, libido, mood, energy. Note any GI, insomnia, or restlessness.
• Week 8: Repeat total-T, free-T, SHBG, cortisol, ALT/AST. Compare to baseline.
• Week 12 (if continuing): Repeat full hormonal panel; if hematocrit is being co-tracked, recheck.
• Months 6+ continuous use: Repeat LFTs + full hormone panel quarterly. If LFT trending upward, drop dose or discontinue.

Post-cycle / washout

• 2-4 weeks off, then repeat free-T + SHBG to verify the on-cycle changes were drug-mediated and not regression to baseline / placebo.